Clinical Trials Logo

Colorectal Neoplasms Malignant clinical trials

View clinical trials related to Colorectal Neoplasms Malignant.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04873895 Terminated - Clinical trials for Colorectal Neoplasms Malignant

TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)

TACE-Ax-HCQ
Start date: January 24, 2022
Phase: Phase 1
Study type: Interventional

Liver metastases are a leading cause of death among patients with metastatic colorectal cancer. Duration of disease control is short following 2nd-line or later systemic therapy. Liver-directed therapy such as TACE has a higher response rate and improves progression-free survival (PFS), but the benefit is still limited. Cancer cells escape ischemic cell death via autophagy and hypoxia-inducible factor (HIF) activation. We hypothesize that blocking autophagy and the vascular endothelial growth factor (VEGF) pathway will improve both response and PFS following TACE.